Abstract:Abstract The use of induced pluripotent stem cells (iPSCs) to derive immune effector cells offers distinct advantages for immune therapy over existing patient- or donor- derived platforms, not only in terms of scalable manufacturing and precision genetic engineering at the clonal level, but also in allowing the generation and combinational use of multiple effector cell types each with distinct characteristics. Taking cues from the natural propagation of innate to adaptive effector responses, here we describe the combined use of multi-engineered iPSC derived Natural Killer (iNK) and T (iT) cell platforms in order to exploit the unique properties of each cell type to achieve both depth and durability of response for hematological malignancies. As innate cells, NK cells are characterized by the capacity for spontaneous reactivity, either in response to cell surface antigen or downregulation of class I MHC, and the rapid kinetic under which NK cells operate make them an ideal candidate to achieve a depth of response that outpaces the limiting effects of cytokine support. FT596 was developed as a dual-targeted iNK cell platform engineered to express both a CD19-directed, NK cell-optimized (NKG2D-2B4-CD3ζ) chimeric antigen receptor (CAR) and a high-affinity, non-cleavable Fc receptor (hnCD16), enabling multi-targeting through combination with therapeutic antibodies. The activity of each receptor is further enhanced by the expression of an IL15-IL15Ra fusion receptor, which also allows the cells to expand in the absence of exogenous cytokine support and prolongs cell survival in vitro and in vivo. T cells are exquisitely specific and undergo rapid clonal expansion and differentiation in response to target antigen, and antigen driven persistence has been demonstrated as a key determinant in efficacy in primary CAR-T cell immune therapy. FT819 is an iT cell platform engineered to express a functionally optimized CD19-CAR (1XX) that has been genome edited into the T cell receptor (TCR) alpha constant (TRAC) locus to provide ideal CAR activity and to prevent TCR expression, thereby avoiding the complications of GVH reactivity in an allogeneic setting. In vivo, both FT596 and FT819 showed stable levels of tumor cell clearance against the CD19+ acute lymphoblastic leukemia cell line NALM6, comparable to that of primary CAR19 T cells (p*<0.0001 for FT596, FT819 or Primary CART vs NALM6 alone). FT596 also shows enhanced clearance of CD19+CD20+ Burkitts lymphoma cell line RAJI when used in combination with rituximab (p=0.0002 vs rituximab alone). Collectively, these studies suggest a compounded anti-tumor effect can be achieved utilizing the inherent properties of engineered CAR-iNK cells together with therapeutic antibody combined with engineered CAR-iT cells which will be highlighted in this presentation. Citation Format: Jode P. Goodridge, John W. Reiser, Ryan Bjordahl, Milli Mandal, Chia-wei Chang, Raedun Clarck, Sajid Mahmood, Huang Zhu, Svetlana Gaidarova, Robert Blum, Frank Cichocki, Hui-ting Hsu, Greg Bonello, Tom Lee, Brian Groff, Karl-Johan Mamlberg, Bruce Walcheck, Jeffrey S. Miller, Dan Kaufman, Bahram Valamehr. Combinational strategy targeting B cell malignancy using iPSC engineered CAR-NK (FT596) and CAR-T cell (FT819) platforms with therapeutic antibody to achieve an effective deep and durable response [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2216.

Engineering de novo binder CAR-T cell therapies with generative AI

Immu-01. De Novo-Designed Binder-Based Car T Cells Enable Effective Targeting Of Glioblastoma

Artificial Intelligence-Powered Molecular Docking and Steered Molecular Dynamics for Accurate scFv Selection of Anti-CD30 Chimeric Antigen Receptors

Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing

De novo designed pMHC binders facilitate T cell induced killing of cancer cells

CAR immune cells: design principles, resistance and the next generation

Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells

Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells

Direct in vivo CAR T cell engineering

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

Abstract 5240: Novel CD3-Fusion Receptor enables combination of T-cell engagers and allogeneic CAR T cells to promote enhanced antitumor activity and overcome antigen escape

Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance

Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells

Abstract 2216: Combinational Strategy Targeting B Cell Malignancy Using Ipsc Engineered CAR-NK (FT596) and CAR-T Cell (FT819) Platforms with Therapeutic Antibody to Achieve an Effective Deep and Durable Response

Abstract 3207: Preclinical Development of First-of-kind Dual-Targeted Off-the-shelf CAR-NK Cell Product with Engineered Persistence for an Effective Treatment of B Cell Malignancies

Challenges and future perspectives for high-throughput chimeric antigen receptor T cell discovery

CAR T cells: Building on the CD19 paradigm

Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer

A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells